Philip Morris International’s U.S. businesses have opened a new manufacturing campus in Aurora, Colorado, representing a planned investment of approximately $1.2 billion between 2024 and 2028.
The facility began commercial production in July 2026 and manufactures ZYN nicotine pouches. It joins PMI’s existing U.S. manufacturing operations in Owensboro, Kentucky, and Wilson, North Carolina.
Located on a 148-acre property, the approximately 780,000-square-foot campus is PMI’s first newly constructed manufacturing and production complex in the United States. The company said the project progressed from the start of construction to commercial shipments in approximately 19 months.
PMI initially announced the Aurora development as a $600 million project in 2024. The planned investment has since doubled as the company added production capacity, expanded the site and introduced additional infrastructure and manufacturing capabilities.
Approximately $1 billion of the planned $1.2 billion investment has already been incurred. The remaining capital is expected to support further development through 2028 as PMI responds to demand for ZYN in the United States and prepares the facility to serve international markets.
The campus integrates manufacturing, packaging, warehousing and distribution within one location. This structure is intended to improve operational efficiency and strengthen PMI’s supply chain by reducing reliance on any single production facility.
The Aurora operation is also being positioned as an export hub serving markets across Asia, Latin America and the Caribbean.
PMI expects the campus to directly employ approximately 500 people in production, engineering, quality control, technical and support roles.
Construction was projected to support nearly 5,000 jobs and generate close to $1 billion in economic activity. Once fully operational, the facility is expected to produce approximately $550 million in annual economic impact and support about 1,000 indirect jobs, according to an economic study cited by PMI.
The company has also contributed more than $1.5 million to Colorado organizations since 2024, including groups supporting veterans, utility assistance and workforce education.
The facility’s opening follows the U.S. Food and Drug Administration’s authorization of 20 ZYN products as modified-risk tobacco products in June 2026. The authorization allows PMI to communicate specified reduced-risk information relative to cigarettes under the conditions established by the agency.
KEY QUOTE:
“This facility expands our production capacity, strengthens our supply chain, and enhances our ability to serve growing demand in the United States and around the world.”
Stacey Kennedy, CEO of PMI U.S.
